FDA accepts supplemental Biologics Licence Application for Roche’s Polivy combination
The acceptance has been given for people with previously untreated diffuse large B-cell lymphoma
The US Food and Drug Administration (FDA) has accepted the Roche’s supplemental Biologics License Application (sBLA) for Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL). The FDA is expected to make a decision on approval by 2nd April, 2023, a statement from Roche has notified.
The statement also said that the sBLA is based on results from the pivotal phase-III Polarix trial, which is the first in two decades to show a clinically meaningful improvement in Progression-Free Survival (PFS) compared to the current standard of care Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). The risk of disease progression, relapse or death was reduced by 27 per cent with Polivy plus R-CHP compared with R-CHOP after a median follow-up of 28.2 months (hazard ratio [HR] 0.73; 95% confidence interval [CI]: 0.57–0.95; p<0.02). Safety outcomes were consistent with those seen in previous clinical trials, and the safety profile was comparable for Polivy plus R-CHP versus R-CHOP, including rates of grade 3-4 adverse events (AEs; 57.7% versus 57.5%), serious AEs (34.0% versus 30.6%), grade 5 AEs (3.0% versus 2.3%), and AEs leading to dose reduction (9.2% versus 13.0%).
Based on pivotal data from the Polarix study, the European Commission approved Polivy in combination with R-CHP in May 2022 for the treatment of adult patients with previously untreated DLBCL. Polivy is currently approved as a readily available, fixed-duration treatment option for relapsed or refractory (R/R) DLBCL in combination with bendamustine and Mabthera/Rituxan in more than 70 countries worldwide, including in the EU and in the US, the statement added.